Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 28 studies | 30% ± 11% | |
fibroblast | 17 studies | 29% ± 11% | |
astrocyte | 15 studies | 56% ± 23% | |
capillary endothelial cell | 13 studies | 29% ± 6% | |
oligodendrocyte precursor cell | 12 studies | 47% ± 21% | |
smooth muscle cell | 12 studies | 26% ± 6% | |
endothelial cell of lymphatic vessel | 11 studies | 38% ± 18% | |
endothelial cell of artery | 9 studies | 33% ± 13% | |
vein endothelial cell | 9 studies | 32% ± 16% | |
pericyte | 8 studies | 23% ± 5% | |
connective tissue cell | 5 studies | 23% ± 10% | |
myofibroblast cell | 5 studies | 36% ± 10% | |
cardiac muscle cell | 5 studies | 58% ± 8% | |
Mueller cell | 5 studies | 42% ± 14% | |
glomerular endothelial cell | 3 studies | 37% ± 11% | |
glial cell | 3 studies | 21% ± 5% | |
epithelial cell | 3 studies | 40% ± 16% | |
endocardial cell | 3 studies | 44% ± 9% | |
endothelial cell of vascular tree | 3 studies | 47% ± 15% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
heart | 5 studies | 33% ± 7% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
ovary | 93% | 8590.28 | 168 / 180 | 77% | 12.60 | 330 / 430 |
brain | 68% | 2231.75 | 1795 / 2642 | 85% | 14.53 | 598 / 705 |
lung | 95% | 8826.85 | 551 / 578 | 41% | 5.09 | 477 / 1155 |
esophagus | 87% | 10402.34 | 1264 / 1445 | 31% | 4.28 | 56 / 183 |
stomach | 89% | 7673.81 | 318 / 359 | 28% | 3.64 | 81 / 286 |
uterus | 92% | 7686.48 | 156 / 170 | 25% | 7.90 | 114 / 459 |
prostate | 86% | 5509.70 | 210 / 245 | 30% | 1.14 | 151 / 502 |
intestine | 93% | 8807.24 | 900 / 966 | 15% | 1.81 | 77 / 527 |
bladder | 90% | 11988.52 | 19 / 21 | 16% | 1.46 | 80 / 504 |
spleen | 100% | 8403.10 | 241 / 241 | 0% | 0 | 0 / 0 |
breast | 94% | 6639.44 | 430 / 459 | 5% | 0.25 | 60 / 1118 |
thymus | 87% | 3657.37 | 567 / 653 | 11% | 0.77 | 69 / 605 |
heart | 97% | 7198.80 | 834 / 861 | 0% | 0 | 0 / 0 |
adipose | 97% | 7704.33 | 1162 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 95% | 7327.64 | 1270 / 1335 | 0% | 0 | 0 / 0 |
adrenal gland | 71% | 1977.01 | 184 / 258 | 19% | 2.61 | 43 / 230 |
skin | 65% | 2171.09 | 1173 / 1809 | 12% | 2.12 | 58 / 472 |
kidney | 43% | 1224.51 | 38 / 89 | 26% | 1.50 | 237 / 901 |
pancreas | 25% | 498.00 | 81 / 328 | 39% | 2.00 | 70 / 178 |
muscle | 56% | 1294.81 | 448 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 24% | 1.44 | 19 / 80 |
tonsil | 0% | 0 | 0 / 0 | 11% | 0.57 | 5 / 45 |
liver | 4% | 65.41 | 9 / 226 | 6% | 0.37 | 26 / 406 |
peripheral blood | 0% | 1.68 | 1 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0006915 | Biological process | apoptotic process |
GO_0006366 | Biological process | transcription by RNA polymerase II |
GO_0001525 | Biological process | angiogenesis |
GO_0001666 | Biological process | response to hypoxia |
GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
GO_0016607 | Cellular component | nuclear speck |
GO_0005739 | Cellular component | mitochondrion |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0000785 | Cellular component | chromatin |
GO_0005886 | Cellular component | plasma membrane |
GO_0000978 | Molecular function | RNA polymerase II cis-regulatory region sequence-specific DNA binding |
GO_0046983 | Molecular function | protein dimerization activity |
GO_0000977 | Molecular function | RNA polymerase II transcription regulatory region sequence-specific DNA binding |
GO_0000981 | Molecular function | DNA-binding transcription factor activity, RNA polymerase II-specific |
Gene name | HIF3A |
Protein name | Hypoxia inducible factor 3 subunit alpha Hypoxia-inducible factor 3 alpha subunit Hypoxia inducible factor 3 subunit alpha (Hypoxia inducible factor 3, alpha subunit, isoform CRA_a) Hypoxia-inducible factor 3-alpha (HIF-3-alpha) (HIF3-alpha) (Basic-helix-loop-helix-PAS protein MOP7) (Class E basic helix-loop-helix protein 17) (bHLHe17) (HIF3-alpha-1) (Inhibitory PAS domain protein) (IPAS) (Member of PAS protein 7) (PAS domain-containing protein 7) |
Synonyms | hCG_21095 PASD7 MOP7 BHLHE17 |
Description | FUNCTION: Acts as a transcriptional regulator in adaptive response to low oxygen tension. Acts as a regulator of hypoxia-inducible gene expression . Functions as an inhibitor of angiogenesis in hypoxic cells of the cornea. Plays a role in the development of the cardiorespiratory system. May also be involved in apoptosis (By similarity). .; FUNCTION: [Isoform 2]: Attenuates the ability of transcription factor HIF1A to bind to hypoxia-responsive elements (HRE) located within the enhancer/promoter of hypoxia-inducible target genes and hence inhibits HRE-driven transcriptional activation. Also inhibits hypoxia-inducible ARNT-mediated gene expression. .; FUNCTION: [Isoform 3]: Attenuates the ability of transcription factor HIF1A to bind to hypoxia-responsive elements (HRE) located within the enhancer/promoter of hypoxia-inducible target genes and hence inhibits HRE-driven transcriptional activation. .; FUNCTION: [Isoform 4]: Attenuates the ability of transcription factor HIF1A and EPAS1/HIF2A to bind to hypoxia-responsive elements (HRE) located within the enhancer/promoter of hypoxia-inducible target genes and hence inhibits HRE-driven transcriptional activation . May act as a tumor suppressor and inhibits malignant cell transformation . .; FUNCTION: [Isoform 5]: Attenuates the ability of transcription factor HIF1A to bind to hypoxia-responsive elements (HRE) located within the enhancer/promoter of hypoxia-inducible target genes and hence inhibits HRE-driven transcriptional activation. . |
Accessions | O95262 ENST00000300862.7 [Q9Y2N7-2] H0YE02 Q9Y2N7 H0YDZ5 ENST00000531043.1 ENST00000533789.5 ENST00000600879.5 ENST00000528563.5 E9PJR0 E9PNQ7 ENST00000526506.5 ENST00000600383.1 ENST00000244303.10 [Q9Y2N7-7] E9PLC8 ENST00000472815.5 ENST00000533145.5 M0R104 ENST00000377670.9 [Q9Y2N7-1] |